Soluble tumour necrosis factor receptor type II and survival in colorectal cancer

Ana Babic, Sonali M. Shah, Mingyang Song, Kana Wu, Jeffrey A. Meyerhardt, Shuji Ogino, Chen Yuan, Edward L. Giovannucci, Andrew T. Chan, Meir J. Stampfer, Charles S. Fuchs, Kimmie Ng

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Background:Chronic inflammation may play a role in colorectal cancer (CRC) pathogenesis. The relationship between soluble tumour necrosis factor receptor type II (sTNF-RII) and survival among CRC patients is not well defined.Methods:We prospectively evaluated the association between pre-diagnosis plasma levels of sTNF-RII and mortality in 544 CRC patients from the Nurses' Health Study and Health Professionals Follow-Up Study diagnosed from 1990 to 2010. Primary and secondary end points were overall and CRC-specific mortality, respectively. Cox proportional hazards models were used to calculate multivariate hazard ratios for mortality.Results:Higher sTNF-RII levels were significantly associated with increased overall mortality (multivariate HR=1.48, 95% CI 1.02-2.16, P-Trend=0.006), but not with CRC-specific mortality (HR=1.23, 95% CI 0.72-2.08, P-Trend=0.34). In subgroup analyses, among regular aspirin users, those with higher sTNF-RII levels had an adjusted HR of 0.52 (95% CI 0.20-1.33) for overall mortality compared with those with lower sTNF-RII levels, whereas among nonregular aspirin users the adjusted HR was 2.26 (95% CI 1.23-4.01, P for interaction=0.53).Conclusions:Among CRC patients, higher sTNF-RII levels are associated with a significant increase in overall mortality, but not CRC-specific mortality. The role of inflammation and anti-inflammatory medications in survival of CRC patients warrants further exploration.

Original languageEnglish
Pages (from-to)995-1002
Number of pages8
JournalBritish Journal of Cancer
Volume114
Issue number9
DOIs
StatePublished - 26 Apr 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Soluble tumour necrosis factor receptor type II and survival in colorectal cancer'. Together they form a unique fingerprint.

Cite this